Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Ekopak NV is a Belgian company specializing in sustainable industrial water treatment solutions, operating primarily through two segments: Water-as-a-Service (WaaS) and Non-WaaS (Project Business). Its core purpose is to optimize water usage by designing, building, financing, maintaining, and operating advanced water processing installations that transform alternative sources like rainwater, surface water, and wastewater into reusable ultra-pure water for industrial processes. Key offerings include cooling and process water treatment, boiler feed water systems, ultra-filtration, legionella prevention, disinfection, corrosion control, and chemical supplies, alongside equipment such as reverse osmosis units, water softeners, filtration systems, and wastewater stations. Ekopak NV serves water-intensive sectors including pharmaceuticals, food and beverage, chemicals, pulp and paper, cosmetics, textiles, and manufacturing, helping clients reduce consumption, meet regulatory standards, and achieve circular water management under its 'Reduce. Reuse. Revalue.' philosophy. Founded in 1997 and headquartered in Tielt, Belgium, with around 241-290 employees, the company operates across Europe, Asia Pacific, Africa, and the Americas, emphasizing ESG principles and innovative technologies like closed-circuit reverse osmosis to combat water scarcity and support sustainability goals. In financial markets, Ekopak NV represents a key player in the utilities-regulated water industry, focusing on off-grid, eco-conscious solutions amid rising global demand for water efficiency.
€3.80
€0.02 (-0.52%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-26.86% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 7.3%, steady but not accelerating.
Negative free cash flow of -€20M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€51M
▲ +7.3% YoY
Net Income (TTM)
-€14M
▼ -13.0% YoY
Op. Margin
-26.86%
▲ +0.5pp YoY
ROIC
-8.89%
▲ +0.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€20M
▲ +36.2% YoY
Op. Cash Flow (TTM)
-€8M
▲ +26.3% YoY
Net Debt
€75M
Cash & Equiv.
€8M
3Y CAGR: +42.4%
Continue Research
Ekopak NV (EKOP.XBRU)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Ekopak NV scores 15/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Ekopak NV scores 15 out of 100 on Intrinsiqq's quality score, passing 1 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -26.9% operating margin and a -8.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh EKOP.XBRU's valuation and scores 15/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.